Further to the Company’s announcements dated 9 March 2018 and 13 March 2018 respectively, on behalf of the Board of Directors of UMWH (“Board”), Maybank Investment Bank Berhad (“Maybank IB”) wishes to announce that the Company has been notified by Med-Bumikar and its wholly-owned subsidiary, CSSB, that they have separately rejected the conditional offer made by UMWH for the acquisition of their collective 50.07% equity interest in MBMR ("MBMR Offer").

As the Board is of the opinion that the conditional offer is reasonable, being at a premium to the traded share price, the Board intends to continue to engage Med-Bumikar, CSSB, their respective shareholders and key principals, being the brand owners of the distributorship marques, on the merits of the Proposed MBMR Acquisition for their further consideration. Accordingly, UMWH has notified Med-Bumikar and CSSB respectively in writing of its decision to extend the period for which the MBMR Offer shall continue to be valid, from 28 March 2018 to 30 April 2018.

For the avoidance of doubt and as announced on 9 March 2018, the Proposed MBMR Acquisition and the Proposed Perodua Acquisition are not conditional upon each other.

Notwithstanding, on behalf of UMWH, Maybank IB wishes to emphasise that there is no certainty that the MBMR Offer will lead to any conclusive or definitive understanding between the parties. There is therefore no certainty that UMWH will extend the Proposed MO for all the remaining MBMR Shares not already owned by UMWH and persons acting in concert with it, if any.

An appropriate announcement will be made by the Company as and when there are material developments relating to the Proposed MBMR Acquisition. Shareholders are advised to exercise caution when dealing in MBMR Shares and to seek independent advice if they wish to do so.

This announcement is dated 26 March 2018.